Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Over the last 12 months, insiders at Aurinia Pharmaceuticals Inc. have bought $0 and sold $2.11M worth of Aurinia Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Aurinia Pharmaceuticals Inc. have bought $424,299 and sold $15.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $178,284 was made by MILNE GEORGE M JR (director) on 2023‑03‑02.
2024-11-11 | Sale | director | 4,557 0.0032% | $8.43 | $38,416 | +2.59% | ||
2024-11-11 | Sale | director | 5,241 0.0036% | $8.43 | $44,182 | +2.59% | ||
2024-08-06 | Sale | Chief Commercial Officer | 18,249 0.0121% | $5.31 | $96,902 | +26.69% | ||
2024-05-21 | Sale | director | 4,946 0.0036% | $5.74 | $28,390 | +20.54% | ||
2024-05-21 | Sale | director | 5,252 0.0038% | $5.74 | $30,146 | +20.54% | ||
2024-05-21 | Sale | director | 5,630 0.004% | $5.74 | $32,316 | +20.54% | ||
2024-05-21 | Sale | director | 520 0.0004% | $5.74 | $2,985 | +20.54% | ||
2024-05-21 | Sale | director | 5,610 0.004% | $5.74 | $32,201 | +20.54% | ||
2024-03-06 | Sale | Chief Executive Officer | 126,981 0.0894% | $5.60 | $711,094 | +0.45% | ||
2024-03-06 | Sale | EVP, Ops & Strategy | 40,665 0.0282% | $5.51 | $224,064 | +0.45% | ||
2024-03-06 | Sale | Chief Financial Officer | 34,811 0.0245% | $5.60 | $194,942 | +0.45% | ||
2024-03-06 | Sale | Chief Commercial Officer | 17,777 0.0125% | $5.60 | $99,551 | +0.45% | ||
2024-03-06 | Sale | EVP, General Counsel | 57,745 0.0407% | $5.60 | $323,372 | +0.45% | ||
2024-02-27 | Sale | EVP, Research and Development | 4,930 0.0034% | $6.10 | $30,073 | -7.48% | ||
2024-02-20 | Sale | Chief Commercial Officer | 15,867 0.0108% | $5.48 | $86,951 | +0.18% | ||
2024-02-20 | Sale | EVP, Research and Development | 25,146 0.0171% | $5.48 | $137,800 | +0.18% | ||
2023-05-23 | Sale | director | 8,733 0.0061% | $11.26 | $98,334 | -27.72% | ||
2023-05-23 | Sale | director | 4,650 0.0032% | $11.26 | $52,359 | -27.72% | ||
2023-05-23 | Sale | director | 4,818 0.0034% | $11.26 | $54,251 | -27.72% | ||
2023-05-23 | Sale | director | 4,815 0.0034% | $11.26 | $54,217 | -27.72% |
Greenleaf Peter | Chief Executive Officer | 1522114 1.0631% | $8.88 | 1 | 3 | +37.58% |
Donley Matthew Maxwell | EVP, Ops & Strategy | 584072 0.4079% | $8.88 | 2 | 2 | +67.17% |
Miller Joseph M | Chief Financial Officer | 495928 0.3464% | $8.88 | 1 | 3 | +37.58% |
Habig Scott Michael | Chief Commercial Officer | 456338 0.3187% | $8.88 | 1 | 3 | +81.51% |
Robertson Stephen P. | EVP, General Counsel | 443824 0.31% | $8.88 | 1 | 2 | <0.0001% |
Knappertz Volker | EVP, Research and Development | 319128 0.2229% | $8.88 | 0 | 2 | |
Jayne David R.W. | director | 44364 0.031% | $8.88 | 0 | 2 | |
Billen Daniel | director | 28141 0.0197% | $8.88 | 0 | 2 | |
MacKay-Dunn R. Hector | director | 18595 0.013% | $8.88 | 3 | 2 | +16.06% |
Balakrishnan Brinda | director | 17523 0.0122% | $8.88 | 0 | 1 | |
Bailey Jeffrey Allen | director | 13356 0.0093% | $8.88 | 0 | 1 | |
Leversage Jill | director | 12918 0.009% | $8.88 | 3 | 2 | <0.0001% |
Smith Karen L. | director | 12672 0.0089% | $8.88 | 0 | 1 | |
Solomons Neil | Chief Medical Officer | 90953 0.0635% | $8.88 | 0 | 10 | |
Martin Michael Robert | Chief Business Officer | 89512 0.0625% | $8.88 | 1 | 15 | +80.79% |
MILNE GEORGE M JR | director | 70000 0.0489% | $8.88 | 3 | 0 | +0.26% |
Huizinga Robert Bindert | EVP of Research | 69379 0.0485% | $8.88 | 0 | 6 | |
Colao Massimilano | Chief Commercial Officer | 13495 0.0094% | $8.88 | 0 | 1 | |
Hagan Joseph P | director | 11961 0.0084% | $8.88 | 0 | 2 |
Armistice Capital Llc | $61.42M | 8.57 | 12.26M | +28.57% | +$13.65M | 0.2 | |
BlackRock | $43.4M | 6.06 | 8.66M | -2.89% | -$1.29M | <0.01 | |
Nea Management Company Llc | $19.89M | 2.78 | 3.97M | 0% | +$0 | 0.09 | |
State Street | $13.88M | 1.94 | 2.77M | +2.46% | +$333,074.83 | <0.01 | |
Goldman Sachs | $10.78M | 1.51 | 2.15M | +5.06% | +$519,527.00 | <0.01 | |
Nuveen | $10.32M | 1.44 | 2.06M | -12.46% | -$1.47M | <0.01 | |
Tang Capital Management, LLC | $10.27M | 1.43 | 2.05M | +272.73% | +$7.51M | 0.04 | |
Geode Capital Management | $8.03M | 1.12 | 1.6M | +2.16% | +$170,059.42 | <0.01 | |
The Vanguard Group | $7.67M | 1.07 | 1.53M | +1.4% | +$105,806.19 | <0.0001 | |
Morgan Stanley | $6.53M | 0.91 | 1.3M | -10.36% | -$754,946.95 | <0.0001 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $5.76M | 0.8 | 1.15M | +178.82% | +$3.7M | 0.15 | |
Schroder Investment Management Group | $5.21M | 0.73 | 1.04M | 0% | +$0 | 0.01 | |
Northern Trust | $5.12M | 0.72 | 1.02M | -4.16% | -$222,358.79 | <0.01 | |
Citigroup | $3.8M | 0.53 | 759,269 | -46.41% | -$3.29M | <0.01 | |
683 Capital Management Llc | $3.08M | 0.43 | 615,000 | +179.54% | +$1.98M | 0.33 | |
Charles Schwab | $2.7M | 0.38 | 538,958 | +23% | +$504,842.75 | <0.01 | |
Woodline Partners LP | $2.51M | 0.35 | 500,555 | -22.42% | -$724,641.52 | 0.02 | |
State of Wisconsin Investment Board | $2.19M | 0.31 | 436,882 | +61.12% | +$830,272.30 | 0.01 | |
BNY Mellon | $2.06M | 0.29 | 411,211 | +4.46% | +$88,040.77 | <0.0001 | |
Group One Trading | $1.89M | 0.26 | 377,322 | -44.42% | -$1.51M | 0.03 | |
Gsa Capital Partners Llp | $1.75M | 0.24 | 349,204 | +196.08% | +$1.16M | 0.14 | |
Susquehanna International Group | $1.69M | 0.24 | 337,757 | -67.29% | -$3.48M | <0.01 | |
Nordea Investment Management Ab | $1.55M | 0.22 | 308,500 | +51.67% | +$528,653.00 | <0.01 | |
JPMorgan Chase | $1.54M | 0.22 | 307,931 | +40.54% | +$445,028.48 | <0.0001 | |
Trexquant Investment LP | $1.47M | 0.21 | 294,201 | New | +$1.47M | 0.03 | |
Hudson Bay Capital Management LP | $1.45M | 0.2 | 290,400 | +213.95% | +$991,479.00 | 0.01 | |
Balyasny Asset Management Llc | $1.45M | 0.2 | 288,875 | -67.43% | -$3M | <0.01 | |
Swiss National Bank | $1.35M | 0.19 | 268,500 | 0% | +$0 | <0.01 | |
Citadel Advisors LLC | $1.34M | 0.19 | 268,403 | -53.62% | -$1.55M | <0.01 | |
Jupiter Fund Management | $1.24M | 0.17 | 247,052 | +21.29% | +$217,263.74 | <0.01 | |
Renaissance Technologies | $1.23M | 0.17 | 244,600 | +81.19% | +$548,896.16 | <0.01 | |
Campbell Co Investment Adviser Llc | $1.19M | 0.17 | 237,095 | +2.02% | +$23,466.84 | 0.1 | |
Level Four Advisory Services Llc | $2.13M | 0.17 | 236,800 | 0% | +$0 | 0.09 | |
Credit Suisse | $1.1M | 0.15 | 219,468 | 0% | +$0 | <0.01 | |
UBS | $1.01M | 0.14 | 200,782 | -20.79% | -$264,057.11 | <0.0001 | |
Sunbelt Securities | $928,228.00 | 0.13 | 185,275 | -3.78% | -$36,447.76 | 0.12 | |
Advisory Services Network Llc | $932,311.00 | 0.13 | 186,090 | -1.55% | -$14,714.37 | 0.02 | |
RhumbLine Advisers | $921,285.00 | 0.13 | 183,892 | +1.41% | +$12,765.29 | <0.01 | |
Barclays | $865,000.00 | 0.12 | 172,724 | -20.93% | -$228,980.31 | <0.0001 | |
Qube Research & Technologies | $862,487.00 | 0.12 | 172,153 | New | +$862,487.00 | <0.01 | |
Ubs Asset Management Americas Inc | $802,342.00 | 0.11 | 160,148 | 0% | +$0 | <0.0001 | |
Invesco | $706,685.00 | 0.1 | 141,055 | -2.51% | -$18,206.33 | <0.0001 | |
CalSTRS | $682,803.00 | 0.1 | 136,288 | -5.09% | -$36,638.14 | <0.01 | |
AllianceBernstein | $678,855.00 | 0.1 | 135,500 | 0% | +$0 | <0.0001 | |
Legal & General | $660,113.00 | 0.09 | 131,759 | -0.63% | -$4,188.36 | <0.0001 | |
Bank of America | $583,188.00 | 0.08 | 116,405 | +67.7% | +$235,424.49 | <0.0001 | |
Jane Street Capital | $550,178.00 | 0.08 | 109,816 | -81.15% | -$2.37M | <0.01 | |
Simplex Trading Llc | $543,000.00 | 0.08 | 108,528 | -46.94% | -$480,353.47 | 0.02 | |
Alps Advisors Inc | $511,050.00 | 0.07 | 102,006 | +1.47% | +$7,424.82 | <0.01 | |
Algert Global LLC | $469,000.00 | 0.07 | 93,700 | New | +$469,000.00 | 0.02 |